DrugPatentWatch – Transform Data into Market Domination - Page 3 - Business Intelligence on Biologic and Small Molecule Drugs

Sell to the Drug Patent Cliff: How Biopharma Packaging Companies Win Deals by Tying Serialization and Anti-Counterfeit Solutions to Drug Patent Loss of Exclusivity

The Window You Cannot Miss Every drug patent that expires is a commercial event for at least a dozen industries. […]

Sell to the Drug Patent Cliff: How Biopharma Packaging Companies Win Deals by Tying Serialization and Anti-Counterfeit Solutions to Drug Patent Loss of Exclusivity Read Post »

One Shot: How to Pick the Right Drug Patent for Maximum Drug Patent Term Extension Value

The FDA lets you extend only one patent per drug approval. Most companies leave years of exclusivity on the table

One Shot: How to Pick the Right Drug Patent for Maximum Drug Patent Term Extension Value Read Post »

Drug Patents in Eurasia: What Every Pharma Executive Actually Needs to Know

There is a persistent gap between what Western pharmaceutical executives think they know about drug patent protection in Eurasia and

Drug Patents in Eurasia: What Every Pharma Executive Actually Needs to Know Read Post »

The Art of the Design-Around: Analyzing Drug Formulation Patent Claims to Mitigate Infringement Risk

A Strategic Guide for Pharmaceutical IP Professionals, Formulation Scientists, and Generic Drug Developers Introduction: Why Patent Claims Decide Who Wins

The Art of the Design-Around: Analyzing Drug Formulation Patent Claims to Mitigate Infringement Risk Read Post »

Patent Term Restoration vs. Adjustment: The $300 Billion Clock Pharma Can’t Afford to Misread

Every pharmaceutical patent starts its life with a 20-year timer running from the filing date. By the time a new

Patent Term Restoration vs. Adjustment: The $300 Billion Clock Pharma Can’t Afford to Misread Read Post »

Cut, Keep, or Cash In: The Pharmaceutical Patent Decision Matrix That Separates Winning Portfolios from Expensive Archives

Every patent portfolio in the pharmaceutical industry contains dead weight. Not metaphorically — literally. Compounds whose commercial logic evaporated years

Cut, Keep, or Cash In: The Pharmaceutical Patent Decision Matrix That Separates Winning Portfolios from Expensive Archives Read Post »

Sell to the Drug Patent Cliff: How Biopharma Packaging Companies Win Deals by Tying Serialization and Anti-Counterfeit Solutions to Drug Patent Loss of Exclusivity

One Shot: How to Pick the Right Drug Patent for Maximum Drug Patent Term Extension Value

Drug Patents in Eurasia: What Every Pharma Executive Actually Needs to Know

The Art of the Design-Around: Analyzing Drug Formulation Patent Claims to Mitigate Infringement Risk

Patent Term Restoration vs. Adjustment: The $300 Billion Clock Pharma Can’t Afford to Misread

Cut, Keep, or Cash In: The Pharmaceutical Patent Decision Matrix That Separates Winning Portfolios from Expensive Archives

Know Before You Launch: The Complete Step-by-Step Guide to Freedom-to-Operate Analysis in Pharma

Business Development Guide for Commercial & Market Access Vendors: Sell Before the Drug Patent Clock Runs Out

Drug Patents in Asia-Pacific: A Country-by-Country Guide to How Long Protection Actually Lasts

Subscribe to Free Updates

3,000+ other biopharma execs get our Drug Patent Expiration Alerts. You should too!